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Summary The development of resistance to cisplatin (DDP) occurs rapidly both in vitro and in vivo, and
constitutes a major obstacle to effective therapy. We have previously demonstrated that there is a highly
synergistic interaction between tamoxifen (TAM) and DDP against cell lines representative of three different
human cancers: melanoma, ovarian carcinoma and small-cell lung cancer. The purpose of these studies was to
determine if TAM interferes with the development of resistance to DDP. T-289 melanoma cells and 2008
ovarian cancer cells were cultured with increasing concentrations of DDP ± TAM in an attempt to induce
resistance to DDP. At various time points the cells were removed from culture and the degree of resistance to
DDP was quantitated. Concurrent exposure to TAM and DDP decreased both the rate and the absolute
magnitude of resistance to DDP in both melanoma and ovarian cancer cell lines. In the T-289 cell line the rate
was decreased by a factor of 3.4 + 1.4 (P<0.05), while in the 2008 cell line the rate was decreased by a factor
of 2.4 (P<0.01). TAM decreases the rate as well as the absolute magnitude of in vitro resistance to DDP in
both melanoma and ovarian cancer cell lines. These data suggest that the concurrent administration of TAM
and DDP may result in a delay in the development of resistance to DDP which may have important clinical
implications in the design of DDP-containing regimens.
Our previous clinical studies have demonstrated that tamox-
ifen (TAM) is an important component of a four-drug com-
bination of dacarbazine, carmustine, DDP and TAM in the
treatment of patients with metastatic melanoma (McClay et
al., 1987). Omission of TAM from the regimen resulted in a
decrease in the overall response rate from 51% to 10%
(McClay et al., 1989). Reincorporation of TAM into the
regimen resulted in a return of the response rate to more
than 50% (McClay et al., 1992a). In a recent clinical study
we demonstrated that, in patients with malignant melanoma
documented to be resistant to single-agent DDP, the addition
of TAM to the DDP programme on the next cycle resulted
in a response rate of 30% (McClay et al., 1993a).
Investigation of the interaction between DDP and TAM in
vitro, using the mathematically rigorous technique of median
effect analysis (Chou & Talalay, 1986), demonstrated a high
degree of synergy with respect to cell kill of the human
melanoma cell line T-289 in colony formation assays [com-
bination index at 0.5 fraction affected (CI50) = 0.26] (McClay
et al., 1992b). Our investigations into the mechanism of this
synergy have demonstrated that it is not due to an effect of
TAM on the commonly identified mechanisms of DDP resis-
tance such as decreased DDP uptake, increased levels of
metallothionine or glutathione, or an effect on the formation
or repair of DDP/DNA adducts. Additionally, it is not
dependent on the presence of oestrogen or progesterone
receptors, absolute level or activity of calmodulin or on
protein kinase C (McClay et al., 1992b, 1993b). However, the
DDP/TAM synergy was dependent on the sensitivity of the
cell to TAM. DDP and TAM were still synergistic with
respect to cytotoxicity in a DDP-resistant variant of the
T-289 melanoma cell line, however they were not synergistic
in killing a variant ofthe same cell line selected for resistance
to TAM (McClay et al., 1993b). Synergy was also absent in
another melanoma cell line that was 4-fold resistant to TAM
(McClay et al., 1992b).
To determine if the synergy between TAM and DDP is
present in other human malignancies, we conducted similar
studies using the human small-cell lung cancer line UMC-5
and the human ovarian carcinoma cell line 2008. As was
observed in the T-289 melanoma cells, there was strong
synergy between TAM and DDP in both the UMC-5 cells
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(CIo = 0.38) and the 2008 cells (CIm = 0.63) (McClay et al.,
1993c).
Although the mechanism of synergy between TAM and
DDP is not known at present, we hypothesised that if TAM
can synergise with DDP to overcome DDP resistance then
TAM may also be able to delay the development of DDP
resistance by a similar mechanism. We report here that TAM
can delay the development of DDP resistance in both T-289
and 2008 cells when given concurrently with DDP in cell
culture.
Materials and methods
Cell lines and culture
The T-289 melanoma cell line was derived from a tumour
explant of a patient and has been passaged for >7 years
(Taetle et al., 1987). The 2008 cell line is an ovarian car-
cinoma line derived from a patient with an ovarian serous
cystadenocarcinoma (Andrews et al., 1988). Cells were cul-
tured in 75 cm2 flasks (Corning, Corning, NY, USA) in
RPMI-1640 (Irving Scientific, Santa Ana, CA, USA) supple-
mented with 10% fetal bovine serum, 50figml-' gentamicin
(Gemini Bio-Products, Calabasa, CA, USA), 2mM L-gluta-
mine, 10 nM hydrocortisone, 5fgml-' insulin, 5jgml'
human transferrin, 10nM oestradiol and 5 ngml-' selenium
(Sigma, St Louis, MO, USA).
Drugs and chemicals
DDP (clinical formulation) was obtained from the Drug
Synthesis and Chemistry Branch, Division of Cancer treat-
ment, NCI, Bethesda, MD, USA. TAM was obtained from
ICI Pharmaceuticals (Macclesfield, UK). Sea-plaque low mel-
ting temperature agarose was obtained from FMC Bio-
Products (Rockland, ME, USA).
Induction ofDDP resistance
Resistance to DDP was induced by growing both the T-289
and the 2008 cells in culutre in the continuous presence of
DDP with or without TAM. In both cell lines, initial selec-
tions were performed at concentrations equivalent to the IC90
(concentration inhibiting 90% of growth) of each agent. For
the T-289 cell line, the initial concentration of DDP was
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0.28 iLM, while the starting concentration of TAM was
0.1 M. The ratio of the ICS for DDPFTAM was approx-
imately 2.5:1. This ratio was adhered to as closely as possible
during the concentration escalation. DDP was escalated to a
maxinum of 3.0FM, while TAM was escalated to a maxi-
mum of 1.14 #LM. After each exposure to fresh drug, the cels
were allowed to grow to confluence (coverage of at least 90%
of the flask surface area) before they were split and reseeded
in fresh medium. This typically resulted in new flasks receiv-
ing approximately 600,000 cells at the start of the culture.
The doubling time of the T-289 cells not in drug was 48 h.
After the first exposure to DDP or after exposure to DDP at
a higher concentrations, the doubling time of the cls in-
creased such that the time to reach confluence icreased from
a normal of approximately 7 days to 14-21 days. As the cells
became accustomed to growing at a particular concentration
of drug the doubling time retuned to normal. Prior to
increasing the concentration of either drug or conducting a
colony-formulating assay (CFA), the doubling time of the
cells had to have retuned to normal. This not uncommonly
required 6-8 weeks. Cells were exposed to the same concen-
tration of the drug(s) and allowed to grow to confluence
three times (three seections) before the concentration of the
drug(s) was escalated or a CFA was conducted. After three
selections, an aliquot of cells was removed and grown in
drug-free medium for 3 weeks. These cells were then used in
a CFA to determine DDP sensitivity.
For the 2008 cells the strategy for developing DDP resis-
tance was the same, however the concentrations of DDP and
TAM as well as the ratio were different. The initial concent-
rations were 0.5 $m and 5.0gm for DDP and TAM respec-
tively. The ratio of the IC,. for DDP/TAM was 1:10. This
ratio was maintained throughout the escalation of concentra-
tions for cells treated with both agents. After each exposure
to fresh drug(s) the cells were allowed to grow to confluence
(approximately 7 days), at which time successful cultures
were split and re-exposed to the same concentration of
DDP ± TAM. In contrast to the T-289 melanoma cells,
exposure to DDP did not appreciably alter the doubling time
of the 2008 cells. After three exposures at the same concen-
tration, the cells were exposed to incremental higher concen-
trations of DDP ± TAM at the same ratio. For cells treated
with DDP alone, the concentrations ranged from 0.5FM up
to a maximum of 1.OpM at 0.ILM escalations. For cells
treated with the combination of DDP/TAM, the concentra-
tions for DDP were the same, while the concentrations of
TAM ranged from 5 pM to 10 Lm at 1.0 gLM escalations.
Following each selection series, an aliquot of cells was
removed, grown in drug-free medium for 3 weeks and used in
a CFA to determine DDP sensitivity.
Colonyformation assay
Cells were seeded into 35 mm2 tissue culture dishes (4,000 per
dish) containing complete medium (2008) or 0.2% agarose/
medium layered over a 1% agarose basement layer (T-289).
Dishes received DDP at increasing concentrations and were
incubated for 10 days at 37C with 5% carbon dioxide. After
10 days the colonies were counted. Percntage survival was
calulated with each DDP concentration being exp d as a
percentage of the drug-free control dishes. The T-289 cells
averaged approximately 20 pm in diameter, while the 2008
ovarian carcinoma cells were approximately 15 pm in dia-
meter. In order to ensure at least 32 cells per colony, collec-
tions of healthy-appearing cells that reached a minimum of
125 pm in diameter were considered colonies.
RIwts
Figure I shows the time course for the development of
resistance to DDP ± TAM in the human melanoma T-289
cells. Fold resistance is defined as the ratio of the DDP IC(O
(concentration of drug inhibiting 50% of growth) for the
DDP/TAM combination-treated cells and DDP ICo5 for cells
treated with DDP alone versus the DDP I(5 for the untreat-
ed control cells. The first indication that there might be a
difference in the development of DDP became
apparent after 200 days of selection. At that point, ells
treated with DDP (2.0gm) alone had an I(5 of 20.6gM
compared with an IC" of 13.4 1M for the DDP (2.0pM)/
TAM (0.76pM)-treated cells (see Table I). Control cells had
an IC,, of 8.9 pM. At the completion of the concentration
escalation, cells treated with DDP (3.0gm) alone had an I(o
of % jM cmpared with the cels treated with the DDP
(3.0gM)/TAM (1.14gM) combination, which had an I(o of
40 m.
Owing to the sensitivity of the T-289 cells to DDP in the
growth medium and the slow recovery of the doublng tirm
after chan in DDP concentration, this selection process
required more than 500 days to complete. In order to be sure
that this observation was not simply the result of one experi-
ment in one ceB line, we electd to conduct the same experi-
ment in the 2008 ovarian cancer cell line. This line was
chosen because our previous experience had shown that it
tolerated DDP well and also developed DDP resitance
quickly. Additionally, we have previously demonstrated that
synrg between TAM and DDP, similar to that demon-
strated in the T-289 melanoma cells, was also present in this
cell line (McClay et al., 1993c). It was therefore lkely that we
would be able to confirm or refute the melanoma findings in
a more timely manner.
The 2008 cell line grew at a faster rate (doubling ime
24 h), which facilitated the repetition of the selection experi-
ment three times. Figure 2 shows that DDP istance emerg-







FugWe I Tbe effea of TAM on the development of istance to
DDP in T-289 human mlanoma cells (U, DDP alone; 0, DDP
phls TAM). Fold is defined as the ratio of the IC,O
(concentration of drug inhibiting 500/. of growth) for the DDP/
TAM combnabon-tated cells and the IC2 for cells treated with
DDP alne vers the IC2 for untreated control cells. Each point
represnts DDP sensitivity relative to unselted T-289 cells deter-
mined from tripicate cutures.
Tae I T-289 DDP resistance selcion
DDP Foldb
Selection no. [TAMP [DDPP IC", (iW) DDP resistance
Control 0 0 8.9c
I 0 0.75 8.8 0.99
0.29 0.75 7.5 0.84
2 0 2.0 20.6 2.31
0.76 2.0 13.4 1.5
3 0 3.0 96.0 11.0
1.14 3.0 40 4.5
Brckets indicate concentration ofeach drug used in the selection
process bICS, ofresstatVariant/1C5 ofthecontroline.cAverag of
six experments.
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DDP sensitivity was apparent after selection in the lowest
DDP concentration (38 days), and became staially
significnt after three selections (103 days). The rate of
development of resistance to DDP was reduced by TAM in
each of the three repeats of this ecperimnt. The mean ratio
of the rate of development of resistance in the presence of
DDP alone versus DDP plus TAM selections was 3.46 ± 1.42
(P<0.05).
S lar to the results obtained in the experiment with the
melanoma cell line, concurrent exposure to both TAM and
DDP resulted in a decrease in the absolute magnitude of
resitance. At the start of the DDP escalation programme the
IC,, for the control 2008 cells was 0.08gm. After three
escalations, the IC,O for the DDP (0.7pm) alone-treated cells
was 0.39pM, while the IC,, for the DDP (0.7pLM)/TAM
(7.0 hiM)-treated cells was 0.22 M (see Table II). The DDP
alone-treated cells developed 10-fold resistance to DDP com-
pared with the DDP/TAM-treated cells, which developed
only 3-fold ran. Thus, in both the T-289 melanoma
and 2008 ovarian carcinoma cell lnes, concurrent exposure
of cells to both DDP and TAM reduced the rate of develop-









Fugpe 2 The effect ofTAM on thedevelopment of resistance to
DDP in 2008 human ovarian carcinoma cells (U, DDPalone; 0,
DDP plus TAM). Fold ance is defined as the ratio of the IC,, (concentration of drug inhtiig 50% of growth) for the
DDP/TAM combination-treated cells and the IC,, for cells
treated with DDP alone versu the IC" for untreated control
cdls. Each point repsents the mean DDP sensitivity rdative to
unselece 2008 cells determined from thre separate repeats of
the expeiment, each performed with triplite cultues.
Tabek 2 2008 DDP resistance selection
DDP" Foldc
Selection no. [TAMj [DDPft IC, (AW) DDP resistance
Control 0 0 0.077
I 0 0.5 0.20 2.55
5 0.5 0.15 1.99
2 0 0.6 0.34 4.45
6 0.6 0.24 3.06
3 0 0.7 0.39 5.09
7 0.7 0.22 2.85
4 0 0.8 0.5 6.47
8 0.8 0.27 3.50
5 0 0.9 0.42 5.44
9 0.9 0.20 2.59
6 0 1.0 0.74 9.65
10 1.0 0.25 3.17
Braclkets indicate concentration ofeach drug used in the selection
process. bAverage of three c periments. cICs ofresistant variant/IC"
of the control line.
Dbcm
This study demonstrates a novel pharmacodynamic effect of
TAM, namely the ability to delay the emergence of resistance
to DDP in vitro for cell lines representative of two important
types of human nmaignancy, melanoma and ovarian car-
cinoma. In addition to decreasing the rate ofdevelopment of
DDP reistance, TAM also decreases the absolute magnitude
of resistance to DDP that develops over a given period of
time. This may be partculy important for patients in the
early stages of their diseas with small tumour burdens. In
this setting the concurrent use of TAM with DDP may
prevent the early emergence of DDP-rant cells that will
result in the ultimate failure of the treatment rgmen.
While TAM has long been recognised to have cytotoxic
effects of its own (Furr & Jordan, 1984), as well as to
modulate established resistance to DDP (McClay et al.,
1993a, b) and to drugs that are substrates for P-glycoprotein-
mediated efflux (Chatterjee & Harris, 1990), it has not
previously been appreciated that TAM could alter the pro-
cesses that underlie the development of drug resistance. The
mechanism of this effect on the development of DDP resis-
tance is presently unknown. One might expect that the ability
of TAM and DDP to synergistically modulate sensitivity to
each other would be the result ofan effect on the biochemical
pharmacology of one drug on the other, however, as
previously mentioned, we have been unable to identify an
effect of TAM on the cllular phaLmacology of DDP or on
any of the other currently identified mechanisms of DDP
resistance (McClay et al., 1992b). As it is well acepted that
TAM exerts the majority of its effect via the oestrogen
receptor, it is important to note that neither the T-289
melanoma nor the 2008 ovarian cell lines expressed oestrogen
or progesterone receptors detectable by either charcoal-dex-
tran ligand binding assays or enzyme-lined immunoassay
(ELISA) performed on tumours grown as xenografts (Mc-
Clay et al., 1992b). We have also shown that the synergy is
not dependent upon protein kinase C or calmodulin activity
(McClay et al., 1993b). Recent data suggest that the synergis-
tic effect may be mediated via the presence of anti-oestrogen
binding sites (McClay et al., 1993d). Anti-oestrogen binding
sites, by definition, bind TAM but do not bind oestro-
gens.
The fact that DDP resistance is genetically stable over
many cell generations and is expressed in a dominant fashion
in hybrids (Andrews & Howell, 1990) suggests that TAM can
influence a genetic process funamental to the development
of resisance. The failure to identify an effect on the
biochemical pharmacology of either DDP or TAM, coupled
with the observation that TAM can produce synergy (Chou
& Talalay, 1986) with DDP even when added up to 48 h
after the end of a I h exposure to DDP (McClay et al.,
1992b), is also consistent with an effect ofTAM on a genetic
process. To further support a TAM effect on genetic pro-
cesses, TAM has recently been reported to form DNA
adducts in vivo (Han & Liehr, 1992). The fact that TAM can
decrease the development of resistance in cell lines reprsen-
tative of two types of human malignancy indicates that the
biochemical or moklular genetic mechnis responsible for
this interaction are common to multiple cell types.
The question of whether or not the delay in the develop-
ment of DDP riance might be of clical importance
remains to be resolved. While there is strong evidence that
treatment outcome is related to the initial sensitivity of the
tumour to the drugs used (Gazdar et al., 1990), the impor-
tance of the rate of the development of resistance to the
effectiveness of treatment is unkcnown. Should the TAM-
induced delay in the development of resistance be of impor-
tance in patients, one would expect at east an improvement
in disease-free survival and possibly even in overall survival.
As we have demonstrated, TAM has effects on both intrinsic
sensitivity to DDP as well as on the rate of resistance
development. Unfortunately, clinical end points such as
diease-free and overall survival will not allow us to distin-
guish between the importance of these two TAM effects.452 E.F. McCLAY et al.
Further methods will need to be developed to help clarify
these issues.
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